Kieran F Geoghegan
Overview
Explore the profile of Kieran F Geoghegan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1276
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Esquejo R, Salatto C, Delmore J, Albuquerque B, Reyes A, Shi Y, et al.
EBioMedicine
. 2018 Apr;
31:122-132.
PMID: 29673898
Dysregulation of hepatic lipid and cholesterol metabolism is a significant contributor to cardiometabolic health, resulting in excessive liver lipid accumulation and ultimately non-alcoholic steatohepatitis (NASH). Therapeutic activators of the AMP-Activated...
2.
Lintner N, McClure K, Petersen D, Londregan A, Piotrowski D, Wei L, et al.
PLoS Biol
. 2018 Apr;
16(4):e1002628.
PMID: 29664898
[This corrects the article DOI: 10.1371/journal.pbio.2001882.].
3.
Lintner N, McClure K, Petersen D, Londregan A, Piotrowski D, Wei L, et al.
PLoS Biol
. 2017 Mar;
15(3):e2001882.
PMID: 28323820
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in regulating the levels of plasma low-density lipoprotein cholesterol (LDL-C). Here, we demonstrate that the compound PF-06446846 inhibits translation of...
4.
Gertsik N, Am Ende C, Geoghegan K, Nguyen C, Mukherjee P, Mente S, et al.
Cell Chem Biol
. 2017 Jan;
24(1):3-8.
PMID: 28065657
γ-Secretase, a four-subunit transmembrane aspartic proteinase, is a highly valued drug target in Alzheimer's disease and cancer. Despite significant progress in structural studies, the respective molecular mechanisms and binding modes...
5.
Caspers N, Han S, Rajamohan F, Hoth L, Geoghegan K, Subashi T, et al.
Acta Crystallogr F Struct Biol Commun
. 2016 Nov;
72(Pt 11):840-845.
PMID: 27827355
Crystals of phosphorylated JAK1 kinase domain were initially generated in complex with nucleotide (ADP) and magnesium. The tightly bound Mg-ADP at the ATP-binding site proved recalcitrant to ligand displacement. Addition...
6.
Nguyen C, West G, Geoghegan K
Methods Mol Biol
. 2016 Nov;
1513:11-22.
PMID: 27807827
A powerful interplay exists between the recognition of gene families, sensitive techniques in proteomics, and the interrogation of protein function using chemical probes. The most prominent methods, such as affinity...
7.
Geoghegan K
Curr Protoc Protein Sci
. 2016 Nov;
86:15.2.1-15.2.20.
PMID: 27801515
Chemical modification of amino groups in proteins serves a diversity of preparative and analytical purposes. The most prominent is to attach nonpeptide groups with useful properties to proteins. Examples of...
8.
Telliez J, Dowty M, Wang L, Jussif J, Lin T, Li L, et al.
ACS Chem Biol
. 2016 Oct;
11(12):3442-3451.
PMID: 27791347
PF-06651600, a newly discovered potent JAK3-selective inhibitor, is highly efficacious at inhibiting γc cytokine signaling, which is dependent on both JAK1 and JAK3. PF-06651600 allowed the comparison of JAK3-selective inhibition...
9.
Zuhl A, Nolan C, Brodney M, Niessen S, Atchison K, Houle C, et al.
Nat Commun
. 2016 Oct;
7:13042.
PMID: 27727204
Inhibition of β-secretase BACE1 is considered one of the most promising approaches for treating Alzheimer's disease. Several structurally distinct BACE1 inhibitors have been withdrawn from development after inducing ocular toxicity...
10.
Liu S, Dakin L, Xing L, Withka J, Sahasrabudhe P, Li W, et al.
Sci Rep
. 2016 Aug;
6:30859.
PMID: 27527709
Interleukin-17A (IL-17A) is a principal driver of multiple inflammatory and immune disorders. Antibodies that neutralize IL-17A or its receptor (IL-17RA) deliver efficacy in autoimmune diseases, but no small-molecule IL-17A antagonists...